AMRING PHARMACEUTICALS INC.

AMRING Pharmaceuticals Inc. specializes in single-use surgical devices, primarily focusing on scalpels. Their portfolio includes both general surgical scalpels and specialized products like Lacrifill Canalicular Gel, which is designed specifically for ocular procedures to aid in precise tissue incision and wound care. These devices are intended for use in surgical settings where sterility and precision are critical.

AMRING Pharmaceuticals Inc. is based in the United States. Since the company operates within the U.S., its devices are subject to regulatory oversight by the FDA, including requirements like the Unique Device Identification (UDI) system for traceability and risk-based classification. The U.S. regulatory framework ensures that devices are evaluated based on their risk level and intended use, which determines their classification and compliance requirements.

AMRING Pharmaceuticals Inc.’s devices are listed in the FDA’s Unique Device Identification (UDI) system. This system is a global standard for identifying medical devices, ensuring transparency in the supply chain and aiding in post-market surveillance. Listing in the UDI system helps track devices throughout their lifecycle, from manufacturing to patient use, and supports regulatory compliance.

The classification of AMRING Pharmaceuticals Inc.’s devices is determined by regulatory authorities like the FDA based on factors such as risk level and intended use. For example, scalpels—including single-use and specialized variants like Lacrifill Canalicular Gel—are categorized under risk-based classifications (e.g., Class I, II, or III in the U.S.). Higher-risk devices, such as those used in ocular procedures, may undergo stricter scrutiny to ensure safety and efficacy, while lower-risk devices may have less stringent requirements.